( NASDAQ-NMS:REGN )

News from Regeneron Pharmaceuticals, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 13, 2017, 01:30 ET Regeneron Collaboration Programs Highlighted During Sanofi Analyst Day $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updates related to its collaboration programs with Sanofi, which were highlighted...


Dec 13, 2017, 01:01 ET Regeneron and Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive topline results from a pivotal Phase 2 clinical study of...


Dec 11, 2017, 07:00 ET Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the...


Nov 29, 2017, 07:00 ET Regeneron and Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc., today announced a collaboration to discover and develop new...


Nov 27, 2017, 02:00 ET Regeneron Provides Update on EYLEA® (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from two Phase 2 studies that added the angiopoietin2 (Ang2) antibody...


Nov 15, 2017, 09:30 ET Regeneron Announces Upcoming Investor Conference Presentation $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast a management presentation at the 29th Annual Piper Jaffray Healthcare Conference at...


Nov 08, 2017, 06:30 ET Regeneron Reports Third Quarter 2017 Financial and Operating Results $countyNameToPathMap.put("sp

- Third quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 12% to $953 million versus third quarter 2016 -...


Nov 07, 2017, 08:00 ET Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017 $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new data analyses from the Praluent® (alirocumab) Injection ODYSSEY...


Nov 01, 2017, 09:00 ET Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 1 clinical trials of REGN1979 and cemiplimab (REGN2810) in...


Oct 31, 2017, 07:00 ET Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent Asthma $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Phase 3 investigational study evaluating dupilumab in adults and...


Oct 27, 2017, 07:00 ET Regeneron's First Global Day of Service Supports Over 100 Non-Profit and Community Organizations $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today celebrated the company's first ever global Day for Doing Good, a company-wide day of service....


Oct 19, 2017, 14:30 ET Science Magazine Ranks Regeneron #1 Biopharma Employer for Fifth Time $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Science magazine has once again ranked the company as the world's number one...


Oct 16, 2017, 08:00 ET Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive results from a Phase 2 investigational study of dupilumab in...


Oct 11, 2017, 09:30 ET Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017 $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2017 financial and operating results on...


Oct 11, 2017, 08:00 ET Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis $countyNameToPathMap.put("sp

Understand AD: A Day in the Life Raises Awareness of Atopic Dermatitis by Sharing Real Stories from the AD Community, Driving Empathy and...


Oct 05, 2017, 12:30 ET Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab) $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Court of Appeals for the Federal Circuit has ordered a new...


Oct 02, 2017, 07:00 ET Regeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced two new collaborations with the Biomedical Advanced Research and Development...


Sep 28, 2017, 01:00 ET Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has granted marketing authorization for...


Sep 16, 2017, 02:15 ET Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive results from the Phase 3 CAFÉ study of DUPIXENT® (dupilumab) in...


Sep 11, 2017, 01:00 ET Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a...


Sep 08, 2017, 01:00 ET Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...


Aug 31, 2017, 16:01 ET Regeneron Announces Upcoming Investor Conference Presentations $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations as follows: - Morgan Stanley Annual Global...


Aug 25, 2017, 08:00 ET Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017 $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new analyses from Praluent® (alirocumab) Injection clinical trials will...


Aug 14, 2017, 09:06 ET Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory...


Aug 03, 2017, 08:22 ET Accessing the Regeneron Second Quarter 2017 Financial and Operating Results Webcast $countyNameToPathMap.put("sp

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Due to technical difficulties in accessing www.regeneron.com, the second quarter 2017 Financial and...